Skip to Content
Morningstar

Centene Corp - Stock Quote CNC

Morningstar Rating
Rating as of

Morningstar's Centene Corp Stock Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Centene Turns in Strong Q1 on Strength in Medicare Advantage and Medicaid; No FVE Change

Julie Utterback, CFA Senior Equity Analyst

Analyst Note

| Julie Utterback, CFA |

Centene turned in stronger-than-expected first-quarter results, and management increased its outlook for 2022. Even when accounting for these strong trends, our $91 fair value estimate has not changed materially. We continue to see a narrow economic moat around Centene, which maintains strongholds in government-sponsored programs, like Medicaid, the individual exchanges, and Medicare Advantage.

Read Full Analysis

Centene Corp's Company Profile

Business Description

Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of September 2021, mostly in Medicaid (68% of membership), the individual exchanges (10%), Medicare Advantage (6%), and the balance in Tricare (West region), correctional facility, and international plans. The company also serves 4 million users through the Medicare Part D pharmaceutical program.

Contact
7700 Forsyth Boulevard, Centene Plaza
St. Louis, MO, 63105
T +1 314 725-4477
Sector Healthcare
Industry Healthcare Plans
Most Recent Earnings Mar 31, 2022
Fiscal Year End Dec 31, 2022
Stock Type Aggressive Growth
Employees 72,500

Centene Corp's Related News

Stock Strategist Industry Reports

Healthcare Policy Changes Could Result in Opportunities

Expanded insurance rolls would be good news for the managed-care organizations and service providers we cover.
Julie Utterback
Stock Analyst Update

Supreme Court Ruling to Uphold ACA

This decision adds certainty to related health insurance programs.
Julie Utterback
Market Update

The Winners of the New Definition of Infrastructure

Depending on which broader infrastructure projects take shape, numerous companies could see increased demand.
David Sekera
Our Picks

11 Undervalued Climate-Friendly Stocks

These companies are well-positioned for a world less dependent on fossil fuels.
Susan Dziubinski
Stock Strategist Industry Reports

What a Democratic Sweep Means for Healthcare

We think the insurers could be most influenced by potential reforms.
Julie Utterback
Stock Strategist Industry Reports

Election Impact on U.S. Healthcare Looks Modest

Our moat ratings and undervalued view of the MCO and drug/biotech sectors are intact.
Julie Utterback
Commentary

Key ESG Issues Up for Shareholder Vote

Employee welfare and political influence are among the big environmental, social, and governance issues this year.
Jackie Cook
Our Picks

10 Undervalued Stocks With Momentum

These quality stocks have gained more than 15% in the last three months yet still look undervalued to us.
Susan Dziubinski
Stock Strategist Industry Reports

Investing With Our 2020 Healthcare Policy Outlook

We see risks for managed care but also opportunities to own moatworthy companies at sizable discounts.
Jake Strole
Credit Insights

New Issue Corporate Bond Market Reaches a Frenzied Pace

The draw of low interest rates combined with tight credit spreads keeps issuers coming back to the market for more.
David Sekera
Quarter-End Insights

Our Outlook for Health-Care Stocks

With macro-conditions improving, the focus should return to fundamentals in health care.
Alex Morozov
US Videos

Did Health-Care Reform Die in Massachusetts?

Health-care analyst Matt Coffina thinks the odds for health-care reform passing are around 50%, but that either way the impact on industry will be muted.
Pat Dorsey